Liver Enzyme Elevation Risk: Silymarin, NAC, and Berberine With Lifestyle First

For Liver Enzyme Elevation Risk, sustained energy balance, activity, glucose control, and alcohol reduction remain primary. Supplement interventions should be considered adjuncts to this base.

Adjunct options with clinical signal

• Milk Thistle (Silymarin) may improve ALT/AST in selected cohorts.
• N-Acetylcysteine (NAC) supports glutathione pathways and may improve oxidative-stress burden.
• Berberine can improve metabolic drivers that often accompany hepatic stress.

Practical protocol context

Most useful use-case is combined treatment where metabolic pressure is actively addressed.

This often includes overlap management with Non-Alcoholic Fatty Liver Risk, plus ongoing ALT/AST and waist/glucose monitoring.

Limits and safety constraints

Trial heterogeneity is high, endpoints are not always harmonized, and enzyme changes do not always translate directly to long-term fibrosis outcomes. Drug-supplement interactions are possible, especially in polypharmacy contexts.

For these reasons, supplements should be monitored and not treated as stand-alone liver therapy.

Practical summary

• Lifestyle and metabolic correction remain first-line.
• Silymarin, NAC, and berberine can be evidence-aligned adjuncts.
• Longitudinal biomarkers and medication review are necessary.

Sources

1. Younossi ZM et al. (2022). NAFLD/MASLD management update. https://pubmed.ncbi.nlm.nih.gov/35176096/
2. Hagstrom H et al. (2018). Lifestyle and liver-risk progression context. https://pubmed.ncbi.nlm.nih.gov/29683979/
3. Soleimani V et al. (2019). Silymarin and liver-enzyme outcomes. https://pubmed.ncbi.nlm.nih.gov/30032484/
4. Samuni Y et al. (2023). NAC mechanistic and clinical overview. https://pubmed.ncbi.nlm.nih.gov/37924418/
5. Lan J et al. (2022). Berberine and metabolic markers meta-analysis. https://pubmed.ncbi.nlm.nih.gov/34956436/